UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Historical Holders from Q2 2017 to Q1 2025

Symbol
URGN on Nasdaq
CUSIP
M96088105
Type / Class
Equity / Ordinary Shares, par value NIS 0.01 per share
Shares outstanding
46.2M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
36.3M
Holdings value
$386M
% of all portfolios
0.003%
Grand Portfolio weight change
0%
Number of holders
138
Number of buys
65
Number of sells
-58
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Adage Capital Management, L.P. 6.94% $32.4M 2.93M Adage Capital Management, L.P. Dec 31, 2024
MENORA MIVTACHIM HOLDINGS LTD. 4.99% $25.5M 2.3M Menora Mivtachim Holdings Ltd Mar 11, 2025
MORGAN STANLEY 1.8% $8.33M 753K Morgan Stanley Dec 31, 2024

Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 303K $3.35M +$1.25M $11.06 9
2024 Q4 36.3M $386M -$9.61M $10.65 138
2024 Q3 35.1M $446M -$58.5M $12.70 127
2024 Q2 38.2M $641M +$95.8M $16.78 115
2024 Q1 626K $9.38M -$5.64M $15.00 9
2023 Q4 21.4M $321M +$46.8M $15.00 103
2023 Q3 17.7M $248M +$65.7M $14.01 99
2023 Q2 13.2M $137M +$7.29M $10.35 84
2023 Q1 12.4M $115M -$4.57M $9.24 64
2022 Q4 13M $115M -$2.4M $8.87 63
2022 Q3 13.3M $110M -$658K $8.32 55
2022 Q2 13.1M $107M -$6.23M $8.19 58
2022 Q1 14.2M $124M +$1.4M $8.71 81
2021 Q4 14.5M $138M +$2.03M $9.51 68
2021 Q3 14.1M $237M +$1.89M $16.82 89
2021 Q2 12.1M $184M -$6.03M $15.27 76
2021 Q1 14.3M $278M -$4.16M $19.48 88
2020 Q4 14.5M $261M -$10.5M $18.02 80
2020 Q3 15M $289M +$6.24M $19.29 78
2020 Q2 14.7M $382M +$28.3M $26.12 83
2020 Q1 13.3M $237M -$16.6M $17.84 76
2019 Q4 14.2M $473M +$4.84M $33.37 85
2019 Q3 14.6M $347M -$26.2M $23.83 82
2019 Q2 14.7M $527M +$44.8M $35.94 83
2019 Q1 13.5M $497M +$143M $36.94 73
2018 Q4 9.15M $394M +$17.9M $43.06 62
2018 Q3 9.92M $468M +$14.1M $47.23 69
2018 Q2 9.6M $482M +$24.1M $49.76 60
2018 Q1 9.14M $454M +$119M $49.69 43
2017 Q4 6.84M $254M +$70M $37.21 41
2017 Q3 4.6M $144M +$1.64M $31.52 31
2017 Q2 4.72M $85.2M +$85.2M $18.06 20